ライフサイエンスコーパス: artesunate

1 ment of malaria using RDTs, ACTs, and rectal artesunate.

2 42 Malian children treated for malaria with artesunate.

3 t to antimalarial treatment with intravenous artesunate.

4 vely, also received >/=1 dose of intravenous artesunate.

5 or with 250 mg of mefloquine plus 100 mg of artesunate.

6 ere observed in those receiving pyronaridine-artesunate.

7 layed hemolysis, a frequent adverse event of artesunate.

8 double the chemotherapeutic effect of sodium artesunate.

9 ion with chloroquine (high concentration) or artesunate.

10 nergy with chloroquine (CQ), amodiaquine, or artesunate.

11 f two trioxolanes were comparable to that of artesunate.

12 ective combination of mefloquine and 3 days' artesunate.

13 r placebo, 25 mg/kg amodiaquine, or 12 mg/kg artesunate.

14 e currently used derivatives, artemether and artesunate.

15 compared with sulfadoxine/pyrimethamine plus artesunate.

16 alone or in combination with 1 or 3 doses of artesunate.

17 ed on Days 7,14, and 28 after treatment with artesunate.

18 ong patients treated with prereferral rectal artesunate.

19 dvice for those who were treated with rectal artesunate.

20 ho could not take oral medicines with rectal artesunate.

21 ays after first treatment) with pyronaridine-artesunate.

22 n 215 Malian children aged 0.5-15 years with artesunate (0, 24, 48 hours) and amodiaquine (72, 96, 12

23 aridine-artesunate than with mefloquine plus artesunate (10.2% [95% CI, 5.4 to 18.6] vs. 0%; P=0.04 a

24 pyrimethamine (17/129 [13%]) and amodiaquine+artesunate (16/130 [12%]; p=0.854).

25 ally efficacious than clinically used sodium artesunate (2) via both oral and intravenous administrat

26 received 4 weight-based doses of intravenous artesunate (2.4 mg/kg) under a treatment protocol implem

27 Rats were randomly treated with artesunate (2.4 or 4.8 mg/kg i.v.) or vehicle upon resus

28 26% [95% CI 16-36]; p<0.0001) or amodiaquine+artesunate (3/130 [2%]; 33% [24-42]; p<0.0001).

29 ulfadoxine-pyrimethamine; or amodiaquine and artesunate (4 mg/kg daily for 3 days).

30 l, -58% [P = .004]; artesunate-primaquine vs artesunate, -49% [P = .031]) with little difference ther

31 d falciparum malaria were randomized to oral artesunate 6 mg/kg/d as a once-daily or twice-daily dose

32 en aged 1-5 years were Randomized to receive artesunate (7 days) plus primaquine (14 days), artesunat

33 temisinin-piperaquine (86.9%), or mefloquine-artesunate (73.8%).

34 (WT) when treated with the antimalarial drug artesunate (77% versus 38%; P < 0.001).

35 nce-daily or twice-daily dose for 7 days, or artesunate 8 mg/kg/d as a once-daily or twice-daily dose

36 5%) than in groups that received amodiaquine-artesunate (82.3%), dihydroartemisinin-piperaquine (86.9

37 Patients received artesunate, administered orally at a daily dose of eithe

38 Sparse data on the safety of pyronaridine-artesunate after repeated treatment of malaria episodes

39 herefore compared the safety of pyronaridine-artesunate after treatment of the first episode of malar

40 tesunate (7 days) plus primaquine (14 days), artesunate alone or no treatment and followed up activel

41 Artesunate also attenuated cardiac fibrosis and improved

42 with Hz formation, but their sensitivity to artesunate, also thought to be dependent on Hb degradati

43 cidence of gametocytemia was 33.6% following artesunate + amodiaquine (AS + AQ), 7.42% following arte

44 uch higher (36.0%; P < .05) than that of the artesunate-amodiaquine (2.9%) and artesunate-atovaquone-

45 mefantrine (AL, 13 studies), 651 (4.2%) with artesunate-amodiaquine (AA, 6 studies), 7,340 (47.8%) wi

46 14 days of PQ (0.25 mg base/kg) plus either artesunate-amodiaquine (AAQ + PQ) or dihydroartemisinin-

47 risk of recurrent parasitemia, compared with artesunate-amodiaquine (AS/AQ), but changing treatment p

48 ile this difference was near-significant for artesunate-amodiaquine (p = 0.0789) and pyronaridine-art

49 was better tolerated than QnC (p=0.0005) and artesunate-amodiaquine (p<0.0001) in the modified intent

50 te and 8 early failures) were observed after artesunate-amodiaquine and atovaquone-proguanil therapie

51 amodiaquine group, and 15 (75%) of 20 in the artesunate-amodiaquine group infected any number of mosq

52 ients receiving the combination antimalarial artesunate-amodiaquine had a lower risk of death compare

53 Artesunate-amodiaquine is widely used for uncomplicated

54 with artemether-lumefantrine, but not after artesunate-amodiaquine or amodiaquine-sulfadoxine-pyrime

55 plus primaquine, artesunate-amodiaquine, or artesunate-amodiaquine plus primaquine.

56 ised treatment of the fixed-dose combination artesunate-amodiaquine Winthrop((R)) (ASAQ) versus CQ fo

57 ous distribution of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaqui

58 ears old (n = 338) were randomly assigned to artesunate-amodiaquine, atovaquone-proguanil, or artesun

59 er-lumefantrine-amodiaquine plus primaquine, artesunate-amodiaquine, or artesunate-amodiaquine plus p

60 ission was observed following treatment with artesunate-amodiaquine.

61 In large trials, parenteral artesunate (an artemisinin derivative) reduced severe ma

62 Binding of artesunate, an artemisinin monomer, to vimentin prevents

63 artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine) or chloroquine (targ

64 administered initial intravenous therapy (38 artesunate and 49 quinine) followed by oral treatments.

65 emisynthetic artemisinin derivatives such as artesunate and artemether, along with the fully syntheti

66 rivatives of the clinical antimalarial drugs artesunate and artemether, in which a major metabolicall

67 ainst Plasmodium berghei ANKA, comparable to artesunate and artemether.

68 insights into molecular interactions between artesunate and beta-hematin were derived with a combinat

69 = .042) and 33% (P = .015) compared with the artesunate and control arms, respectively.

70 Values for artesunate and dihydroartemisinin were most affected.

71 Pharmacokinetic profiles of artesunate and dihydroartemisinin were similar between s

72 in rodents than the antimalarial drug sodium artesunate and is about 37 times more efficacious than s

73 pies for malaria, including mefloquine (MFQ)-artesunate and lumefantrine (LUM)-artemether.

74 nfections with C2A failed to clear upon oral artesunate and mefloquine treatment alone or in combinat

75 New drugs such as intravenous artesunate and oral artemisinin combinations, with incre

76 ted in a randomized comparison of parenteral artesunate and parenteral quinine in 9 African countries

77 those who could not were treated with rectal artesunate and referred to hospital.

78 NF54 = 7.3 nM) and comparable in potency to artesunate, and 35 exhibited 98% activity in the in vivo

79 % (95% CI, 13.1%-23.1%) for amodiaquine plus artesunate, and 6.7% (95% CI, 3.9%-11.2%) for artemether

80 rodents than either artelinic acid or sodium artesunate, and are strongly inhibitory but not cytotoxi

81 cytotoxic hematin, is potently inhibited by artesunate, and is associated with artesunate metabolism

82 ved pyrimethamine-sulfadoxine and 3 doses of artesunate, and it was 8-fold higher in the group that r

83 iation between an increased risk of MFQ, MFQ-artesunate, and LUM-artemether treatment failures and pf

84 rimethamine, 54 of 491 (11%) for amodiaquine+artesunate, and seven of 502 (1%) for artemether-lumefan

85 malaria treated parenterally with quinine or artesunate, and was recently shown to contribute to dela

86 ality or in hospital discharge rates between artesunate- and quinine-treated patients.

87 Here, we present a rapid screening assay for artesunate antimalarials based on reactive DESI.

88 As artemether and artesunate are derivatives of artemisinin, the beneficia

89 Current artesunate (ARS) regimens for severe malaria are complex

90 Artesunate (ART) is an anti-malaria drug that has been s

91 Artesunate (ART), a semisynthetic derivative of the Arte

92 support for the wider access to pyronaridine-artesunate as an alternative artemisinin-based combinati

93 e semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have

94 Artesunate (AS) induces pitting, a splenic process where

95 Amodiaquine (AQ) is paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in rec

96 Three days of treatment with artesunate (AS)-amodiaquine (AQ) combined with MB was co

97 thamine (SP), SP + amodiaquine (AQ), or SP + artesunate (AS).

98 We gave participants 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72

99 ridoxal 5'-phosphate [PLP]), in complex with artesunate at 2.4- angstrom resolution.

100 hat of the artesunate-amodiaquine (2.9%) and artesunate-atovaquone-proguanil (1.0%) groups.

101 sunate-amodiaquine, atovaquone-proguanil, or artesunate-atovaquone-proguanil treatment groups and fol

102 Artesunate-atovaquone-proguanil was a highly effective a

103 Artesunate-atovaquone-proguanil was not associated with

104 alth Organization has recommended the use of artesunate (ATS) suppositories for emergency treatment o

105 Moreover, artesunate attenuated the HS-induced activation of nucle

106 Artesunate attenuated the multiple organ injury and dysf

107 Artesunate attenuated the organ injury/dysfunction assoc

108 Particularly, artesunate-based antimalarial drugs have been targeted,

109 Artesunate became the most frequent treatment for severe

110 Artesunate binding to vimentin early during infection st

111 Pyronaridine-artesunate can be used to diversify antimalarial therapy

112 hei hypersensitive to the antimalarial drugs artesunate, chloroquine, and atovaquone, resulting in ac

113 Finally, we demonstrate that artesunate, CoA, and dichloroacetate improve TfR1 palmit

114 Little is known on the use of artesunate compared with quinine for the treatment of im

115 Furthermore, artesunate concentration-dependently blocked IgE-mediate

116 Children eligible for rectal artesunate contributed 1.1% of episodes.

117 Post-artesunate delayed hemolysis (PADH) and hyperparasitemia

118 Eight patients had post-artesunate delayed hemolysis that resolved.

119 Post-artesunate delayed hemolysis was detected in 7 children

120 Early treatment with chloroquine or artesunate did not prevent the anemia, suggesting that t

121 relationship between artemisinin treatments (artesunate, dihydroartemisinin, or artemether) and misca

122 and found that dihydroartemisinin (DHA) and artesunate displayed strong cytotoxic effects on HPV-imm

123 Splitting or increasing the artesunate dose did not shorten half-life in either site

124 P. falciparum infections from artesunate efficacy trials in Bangladesh, Cambodia, Laos

125 Pyronaridine-artesunate efficacy was compared with artemether-lumefan

126 Clinical trials of artesunate efficacy were conducted in Bangladesh, in nor

127 o difference was evident between quinine and artesunate either in mortality or in hospital discharge

128 we confirmed that treatment of HS rats with artesunate enhanced the phosphorylation (activation) of

129 Artesunate exhibits pharmacological actions beyond its a

130 A 6-hour lag phase in artificial pitting of artesunate-exposed iRBCs was also observed in vitro.

131 . falciparum malaria treated with parenteral artesunate followed by an oral artemisinin-combination t

132 In patients who had received artesunate for <10 hours, sequestration was higher in fa

133 protocols for early referral and intravenous artesunate for all severe malaria.

134 isinin-based combination therapy, and rectal artesunate for malaria treatment.

135 2), with a switch from quinine to injectable artesunate for management of severe disease and seasonal

136 ed for both Accelerate scenarios, and rectal artesunate for pre-referral treatment at the community l

137 py for uncomplicated malaria and intravenous artesunate for severe malaria due to any Plasmodium spec

138 n-based combination therapy (ACT) and rectal artesunate for severe malaria in children is proven.

139 affects 23% of African children treated with artesunate for severe malaria, of whom more than 15% suf

140 mic African children treated with parenteral artesunate for severe malaria.

141 rtesunate was noninferior to mefloquine plus artesunate for the primary outcome: adequate clinical an

142 ation, providing a foundation for developing artesunate for the treatment of allergic asthma and othe

143 e+sulfadoxine-pyrimethamine, and amodiaquine+artesunate for treatment of uncomplicated malaria in Kam

144 ive pharmaceutical ingredients (for example, artesunate) for incorporation into ACTs.

145 e conventional 5-dose regimen of intravenous artesunate (given at 0, 12, 24, 48, and 72 hours) in Afr

146 artesunate group (50.6%) and the amodiaquine-artesunate group (48.5%) than in the dihydroartemisinin-

147 nificantly more frequently in the mefloquine-artesunate group (50.6%) and the amodiaquine-artesunate

148 in the quinine group (n = 460) and 32 in the artesunate group (n = 1084), corresponding to death rate

149 p<0.0001) or sulfadoxine/pyrimethamine plus artesunate group (one of 198, 1%; p<0.0001).

150 lumefantrine group, 98.5% in the amodiaquine-artesunate group, 99.2% in the dihydroartemisinin-pipera

151 significant difference among the amodiaquine-artesunate group, dihydroartemisinin-piperaquine group,

152 isinin-piperaquine group, and the mefloquine-artesunate group.

153 peraquine group, and 96.8% in the mefloquine-artesunate group; the PCR-adjusted cure rates in the int

154 Two patients receiving mefloquine plus artesunate had seizures.

155 Although rectal artesunate has been touted as a cost-effective pre-refer

156 l role in endoperoxide-induced cytotoxicity (artesunate IC(50) values, 48 h: HeLa cells, 6 +/- 3 muM;

157 litting the dose of the short-half-life drug artesunate improves parasite clearance in falciparum mal

158 Intravenous artesunate improves survival in severe malaria, but clin

159 179 children treated with prereferral rectal artesunate in a multicountry study.

160 estigated potential anti-allergic effects of artesunate in animal models of IgE-dependent anaphylaxis

161 ifferences in treatment coverage with rectal artesunate in children aged <5 years in MUM vs CHW (stan

162 The total dose of artesunate in each group was 12 mg/kg.

163 reatment providers trained to provide rectal artesunate in Ghana, Guinea-Bissau, Tanzania, and Uganda

164 followed up after treatment with parenteral artesunate in Lambarene, Gabon, and Kumasi, Ghana.

165 i-allergic signaling mechanisms of action of artesunate in mast cells were also investigated.

166 g the effects of good manufacturing practice-artesunate in patients with trauma and severe hemorrhage

167 g the effects of good manufacturing practice-artesunate in patients with trauma and severe hemorrhage

168 Organization recommends 3 mg/kg intravenous artesunate in pediatric patients weighing less than 20 k

169 men with a simplified regimen for parenteral artesunate in severe malaria.

170 rum malaria (<1%) who were treated with oral artesunate in Southeast Asia had a parasite clearance ha

171 ole hydrochloride as adjuvant to intravenous artesunate in the treatment of adults with severe falcip

172 Artesunate induces apoptosis, disrupts mitochondrial mem

173 Following profibrotic stimuli, artesunate inhibited proliferation, migration, and contr

174 Rectal artesunate interrupts disease progression by rapidly red

175 take oral drugs received prereferral rectal artesunate irrespective of RDT result and were referred

176 Artesunate is a clinically effective anti-malarial drug

177 Artesunate is a derivative of artemisinin, an active com

178 Artesunate is a semi-synthetic derivative of artemisinin

179 Artesunate is a vital therapy for Plasmodium falciparum

180 Pyronaridine-artesunate is an artemisinin-based combination therapy u

181 Parasite clearance in response to artesunate is faster in Mali than in southeast Asia.

182 treat young children with prereferral rectal artesunate is feasible in remote communities of Africa,

183 For severe malaria, intravenous artesunate is first-line therapy.

184 Parenteral artesunate is recommended as first-line therapy for seve

185 cient fibroblasts, the anti-HCMV activity of artesunate is reduced compared with controls.

186 rogen and the ether-like moieties within the artesunate lactone ring.

187 Deployment of mefloquine-artesunate (MAS3) on the Thailand-Myanmar border has led

188 diagnosis, and administration of intravenous artesunate may avoid fatal outcomes, particularly in fem

189 ed with artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate, or dihydroartemisinin

190 nin-piperaquine plus mefloquine (269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine

191 5% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99])

192 diaquine (AA, 6 studies), 7,340 (47.8%) with artesunate-mefloquine (AM, 25 studies), and 4,639 (30.2%

193 The emergence of artesunate-mefloquine (AS+MQ)-resistant Plasmodium falci

194 A randomized, controlled trial of CQ vs artesunate-mefloquine (AS-MQ) for uncomplicated vivax ma

195 d to receive artemether-lumefantrine (AL) or artesunate-mefloquine (ASMQ) were screened for total imm

196 omly assigned 252 patients to receive either artesunate-mefloquine (n=127) or chloroquine (n=125); 22

197 isation (block sizes of 20), to receive oral artesunate-mefloquine (target dose 12 mg/kg artesunate a

198 within 28 days was lower in patients in the artesunate-mefloquine group (71 [62%; 95% CI 52.2-70.6])

199 Fever clearance was faster in the artesunate-mefloquine group (mean 11.5 h [95% CI 8.3-14.

200 with faster clearance of ring stages in the artesunate-mefloquine group (mean time to 50% clearance

201 as present in 44 (86%) of 51 patients in the artesunate-mefloquine group and 41 (84%) of 49 patients

202 One (<1%) patient in the artesunate-mefloquine group had a serious neuropsychiatr

203 pancy was 2426 days per 1000 patients in the artesunate-mefloquine group versus 2828 days per 1000 pa

204 (84% [95% CI 76-91]) of 115 patients in the artesunate-mefloquine group versus 61 (55% [45-64]) of 1

205 Artesunate-mefloquine is highly efficacious for treatmen

206 tes in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine

207 asite clearance was faster in patients given artesunate-mefloquine than in those given chloroquine (1

208 onotherapy and 5.4 (2.0-14.6, p=0.001) after artesunate-mefloquine therapy.

209 We aimed to compare artesunate-mefloquine with chloroquine to define the opt

210 therapies (ACTs, artemether-lumefantrine and artesunate-mefloquine) where the likelihood of increased

211 temisinin-piperaquine and 5.2% (2.9-7.9) for artesunate-mefloquine.

212 ibited by artesunate, and is associated with artesunate metabolism and susceptibility in drug-pressur

213 Rapid parasite killing by intravenous artesunate might obscure the effects of levamisole.

214 nes dissolved in the DESI spray solution and artesunate molecules exposed on the tablet surface.

215 artemisinin combination therapies (avoiding artesunate monotherapies) and single gametocytocidal low

216 oroquine, Sulfadoxine-Pyrimethamine and oral Artesunate monotherapy.

217 with a fixed-dose combination of mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amod

218 doxine-pyrimethamine (n=507), or amodiaquine+artesunate (n=515), or a 3-day six-dose regimen of artem

219 tment or re-treatment episodes, pyronaridine-artesunate (n=673) day 28 crude ACPR was 92.7% (95% CI 9

220 To evaluate the effects of artesunate on organ injury and dysfunction associated wi

221 ovided good evidence to support an effect of artesunate on the Akt-survival pathway, leading to downr

222 the safety and efficacy of oral pyronaridine-artesunate once daily for 3 consecutive days in adults a

223 of amodiaquine when used in combination with artesunate or another antiviral.

224 ation of 180 mg of pyronaridine and 60 mg of artesunate or with 250 mg of mefloquine plus 100 mg of a

225 sulfadoxine-pyrimethamine, amodiaquine plus artesunate, or artemether-lumefantrine) when diagnosed w

226 fantrine, amodiaquine-artesunate, mefloquine-artesunate, or dihydroartemisinin-piperaquine.

227 te-amodiaquine (p = 0.0789) and pyronaridine-artesunate (p = 0.0519).

228 tandard treatment for severe malaria is with artesunate; patient survival in the 24 hours immediately

229 ly used artemisinin combination therapies of artesunate plus amodiaquine and artemether plus lumefant

230 In Cambodia, artesunate plus mefloquine may be a viable option to tre

231 aged 2-59 months received either one dose of artesunate plus one dose of sulfadoxine-pyrimethamine or

232 in-based combination therapy (ACT) or rectal artesunate plus referral when patients are unable to tak

233 We report here for the first time that artesunate possesses anti-allergic activity by blocking

234 Artesunate prevented IgE-mediated cutaneous vascular hyp

235 parum clinical episodes were observed in the artesunate-primaquine arm.

236 Treatment with artesunate-primaquine reduced the risk of P. vivax episo

237 nate-primaquine vs control, -58% [P = .004]; artesunate-primaquine vs artesunate, -49% [P = .031]) wi

238 ved only in the first 3 months of follow-up (artesunate-primaquine vs control, -58% [P = .004]; artes

239 hours from facilities for injections, rectal artesunate prior to hospital referral can prevent death

240 Compound 5d tested in combination with artesunate produced an additional antiparasitic effect w

241 The clinically used trioxane drug sodium artesunate prolonged mouse average survival to 7.2 days

242 reatment of severe malaria, with intravenous artesunate proving superior to quinine.

243 the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for

244 , community-administered pre-referral rectal artesunate (RAS) should be completed by post-referral tr

245 No evidence was found that pyronaridine-artesunate re-treatment increased safety risk based on l

246 Artesunate reduced parasite clearance time and duration

247 Artesunate reduced posttreatment infectivity dramaticall

248 ulating parasites) and showed a "simplified" artesunate regimen was noninferior to the existing World

249 Artesunate remains the mainstay of treatment for cerebra

250 Artemisinin- and artesunate-resistant Plasmodium chabaudi mutants, AS-ART

251 The findings that pyronaridine-artesunate safety and efficacy were similar on first mal

252 esistance to mefloquine, and also to reduced artesunate sensitivity in vitro.

253 Patients with severe malaria treated with artesunate sometimes experience a delayed hemolytic epis

254 Artesunate-sulfadoxine-pyrimethamine (ASSP) is the front

255 In addition, artesunate suppressed ovalbumin-mediated guinea pig bron

256 erapy for Plasmodium falciparum malaria, but artesunate tablets have been counterfeited on a very lar

257 ed to a set of recently collected suspicious artesunate tablets purchased in shops and pharmacies in

258 Fourteen different artesunate tablets, representative of what can be purcha

259 a until day 42 were higher with pyronaridine-artesunate than with mefloquine plus artesunate (10.2% [

260 ultinational trial assessing the efficacy of artesunate therapy across 11 Southeast Asian sites.

261 phylaxis with sulfadoxine-pyrimethamine plus artesunate to selectively control timing of malaria expo

262 widely administered antimalarials, ART, and artesunate to subdue the erythrocytic phase of the paras

263 icular concern was the positive detection of artesunate traces in the surface of one of the samples,

264 rolling for differences between quinine- and artesunate-treated individuals using the inverse probabi

265 not have contraindications for pyronaridine-artesunate treatment as per the summary of product chara

266 o reduce death from malaria by having rectal artesunate treatment available and used.

267 Increasing the artesunate treatment dose up to 8 mg/kg/d or splitting t

268 Prereferral artesunate treatment is a cost-effective, life-saving in

269 effectiveness of community-based prereferral artesunate treatment of children suspected to have sever

270 Patient fatality rates even with parenteral artesunate treatment remain high.

271 Prereferral rectal artesunate treatment was provided in 272 villages: 109 t

272 rs with parasite half-life assessments after artesunate treatment were analysed.

273 and parasite clearance half-lives following artesunate treatment.

274 art of a clinical trial comparing parenteral artesunate versus quinine (ISRCTN50258054).

275 about 37 times more efficacious than sodium artesunate via subcutaneous administration.

276 airwise comparisons, except amodiaquine plus artesunate vs artemether-lumefantrine, P = .05).

277 database was analyzed to compare outcomes of artesunate vs quinine treatment.

278 n day 42 in the group receiving pyronaridine-artesunate was 83.1% (705 of 848 patients; 95% CI, 80.4

279 that in the group receiving mefloquine plus artesunate was 83.9% (355 of 423 patients; 95% CI, 80.1

280 that in the group receiving mefloquine plus artesunate was 97.8% (360 of 368 patients; 95% CI, 95.8

281 efficacy in the group receiving pyronaridine-artesunate was 99.2% (743 of 749 patients; 95% confidenc

282 Artesunate was a safe and clinically beneficial alternat

283 Artesunate was associated with a faster ICU discharge ra

284 In a country with a high level of care, artesunate was associated with a shorter length of stay

285 Fixed-dose pyronaridine-artesunate was efficacious in the treatment of uncomplic

286 Direct mast cell-stabilizing effect of artesunate was examined in RBL-2H3 mast cell line and in

287 Artesunate was found to inhibit IgE-induced Syk and PLCg

288 Early referral and treatment with artesunate was highly effective for severe malaria from

289 Pyronaridine-artesunate was noninferior to mefloquine plus artesunate

290 Artesunate was rapidly deployed and displayed a robust c

291 severe and complicated malaria (artemether, artesunate) was prompt.

292 S health systems weigh the decision to stock artesunate, we propose a hospital tier framework to info

293 ydroartemisinin-piperaquine and pyronaridine-artesunate were administered as per manufacturer guideli

294 rsonnel (COMs); episodes eligible for rectal artesunate were established through regular household su

295 Anti-allergic actions of artesunate were evaluated in passive cutaneous anaphylax

296 ardized referral and prereferral intravenous artesunate were instituted at district hospitals.

297 acodynamic analysis suggests that 3 doses of artesunate were not inferior to 5 doses for the treatmen

298 amodiaquine and sulfadoxine-pyrimethamine or artesunate were significantly more efficacious, and each

299 id diagnostic tests (RDTs), ACTs, and rectal artesunate when provided by community health workers (CH

300 A combination of artesunate with mefloquine now cures more than 95% of ac